TY - JOUR
T1 - Vaccination against meningococcal disease in Europe
T2 - Review and recommendations for the use of conjugate vaccines
AU - Trotter, Caroline L.
AU - Ramsay, Mary
PY - 2007/1
Y1 - 2007/1
N2 - At the end of 2005, six European countries had implemented public immunization campaigns with serogroup C conjugate vaccines, and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W135 are infrequent causes of disease. This paper outlines recommendations on the use of conjugate vaccines in Europe based on the experience with meningococcal C conjugate (MCC) vaccines so far.
AB - At the end of 2005, six European countries had implemented public immunization campaigns with serogroup C conjugate vaccines, and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W135 are infrequent causes of disease. This paper outlines recommendations on the use of conjugate vaccines in Europe based on the experience with meningococcal C conjugate (MCC) vaccines so far.
KW - Epidemiology
KW - Europe
KW - Meningococcal disease
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=33846036518&partnerID=8YFLogxK
U2 - 10.1111/j.1574-6976.2006.00053.x
DO - 10.1111/j.1574-6976.2006.00053.x
M3 - Review article
C2 - 17168998
AN - SCOPUS:33846036518
SN - 0168-6445
VL - 31
SP - 101
EP - 107
JO - FEMS Microbiology Reviews
JF - FEMS Microbiology Reviews
IS - 1
ER -
